New drug duo targets aggressive breast Cancer's weak spots
NCT ID NCT06008275
Summary
This early-stage trial is testing the safety and effectiveness of combining two drugs, neratinib and ruxolitinib, for a difficult-to-treat form of breast cancer. It is for people whose triple-negative breast cancer has spread and returned to the chest wall after previous chemotherapy. The goal is to see if blocking two specific cancer growth pathways at once can better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.